摘要
目的:评估变应原特异性舌下含服免疫治疗(sublingual immunotherapy,SLIT)儿童过敏性哮喘的临床疗效及安全性。方法:62例儿童过敏性哮喘患者随机分为两组,即SLIT组及对照组。SLIT组(n=31)在对症治疗基础上加用2年SLIT;对照组(n=31)仅对症治疗。比较治疗前后的哮喘症状评分、用药评分、肺功能以及不良反应发生情况。结果:SLIT组患者的哮喘症状评分、用药评分、肺功能指标与对照组比较明显改善,差异有统计学意义(P<0.01)。SLIT组无严重不良事件发生。结论:变应原特异性舌下含服免疫治疗螨诱导的儿童过敏性哮喘安全有效。
Objective To evaluate the safety and efficacy of sublingual immunotherapy( SLIT) to Children with Allergic Asthma. Method 62 patients were randomly assigned two groups. 31 patients were assigned to receive sublingual immunotherapy for two years,31 patients were assigned to receive no SLIT only symptomatic therapy. Asthma symptoms score,drug score,pulmonary function,adverse effect were assessed during the study. Results The asthma symptoms score,drug score and pulmonary function of SLIT groups all improved significantly after the treatment with SLIT compared to control group( P〈0. 01). No severe adverse events occurred in SLIT group. Conclusion SLIT is efficacious and safe to Children with allergic asthma induced by mite.
出处
《吉林医学》
CAS
2015年第16期3491-3493,共3页
Jilin Medical Journal
关键词
哮喘
过敏性
儿童
免疫疗法
舌下
Asthma
Allergic
Children
Immunotherapy
Sublingual